The research, focused on radiological treatment and lasting three years, involves about twenty hospitals
The Association Against Cancer in Tarragona has granted this Thursday a grant of 150,000 euros for research on metastatic breast cancer led by Dr. Jorge Joven, professor of Medicine and director of the Biomedical Research Unit of the Pere Virgili Health Research Institute and the URV. The research focuses on radiological treatment for these tumors and will study 2,500 candidates from around twenty hospitals in Spain with images and molecular analysis for three years. According to Joven, the research will improve the quality of life of patients and extend survival.
Twenty hospital centers throughout the Spanish state will participate in the study. In the case of Camp de Tarragona, the Sant Joan de Reus hospital will take part. The research will last for three years with 2,500 patients with metastatic breast cancer. The objective is to improve the quality of life, but also survival.
To draw conclusions, the researchers will study with images and molecularly the candidates who receive ablative stereotactic, a type of radiotherapy that emits high doses of radiation in very specific locations. This therapy protects healthy tissue while precisely eliminating tumors. According to the AECC, half of cancer patients receive this treatment.
First research in Tarragona with a grant from the AECC
Currently, the Association Against Cancer has 565 research projects underway with a budget of 104 million euros and, for the first time, it has granted this aid to research initiated in the Tarragona demarcation. The work is led by Dr. Jorge Joven and has been included in the AECC Strategic Projects, for which he will receive an economic endowment of 150,000 euros. According to the president of the Tarragona Association Against Cancer, Fede Adán, the Scientific Foundation of the Spanish Association Against Cancer has chosen this research to promote the scarce research and advances in this field. Adán has insisted on the importance of investing in cancer research when it comes to obtaining new tools for early diagnosis, but also in more specific and more effective treatments. At the same time, he has called on researchers from Tarragona to join this line of annual grants to provide financially for their cancer research in upcoming calls.
